Skip to content

Comparing Pain Relief of Nalbuphine and Butorphanol with Ropivacaine in Abdominal and Leg surgeries

Comparison of the analgesic efficacy of nalbuphine versus butorphanol as an adjuvant to 0.75 percentage hyperbaric ropivacaine in lower abdominal and lower limb surgeries - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072624
Enrollment
60
Registered
2024-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: GROUP N(0.75% hyperbaric ropivacaine and nalbuphine): 0.75% hyperbaric ropivacaine 2.2 ml (16.5 mg)+0.8 ml (0.8mg) of nalbuphine (N) intrathecally once. Post operative analgesic efficac

Sponsors

DR MRIDULA T V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA physical status 1 and 2 2. BMI range of 18.5 to 24.9

Exclusion criteria

Exclusion criteria: 1.Infection at the site 2.Spinal deformity such as kyphoscoliosis 3.Bleeding disorders 4.Allergic reaction to study drugs 5.Patients on tranquilizers,hypnotics,sedatives and other psychotropic drugs

Design outcomes

Primary

MeasureTime frame
Postoperative analgesic durationTimepoint: Pain assessment 2 hourlies until 12 hours

Secondary

MeasureTime frame
Duration of motor blockadeTimepoint: Assessed 2 hourlies until 12 hours of post surgery;Duration of sensory blockadeTimepoint: Assessed 2 hourlies until 12 hours of post surgery;The onset of sensory and motor blockade Timepoint: Assessed immediately after spinal injection then, every 3 minutes until 15 minutes, then every 10 minutes upto 1 hour, then every 30 minutes upto 2 hours and then hourly till the end of the surgery

Countries

India

Contacts

Public ContactDR Jyothi B

Karnataka Institute of Medical Sciences

drjyothib1@gmail.com9886187056

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026